CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 273 enrolled
Drug / intervention
Eversense® CGM Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03908125
NCT03908125N/ACompleted
CompareCT.gov

A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System

Senseonics, Inc.·interventional·Posted Apr 9, 2019·Updated Jun 12, 2025

In Brief

A clinical study evaluating Eversense® CGM System for Diabetes Mellitus and 2 related conditions. Completed, enrolled 273 participants across 17 sites.

Detailed Summary

A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the Eversense® CGM System

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 9, 2019
Enrollment StartMar 19, 2019
Primary CompletionFeb 1, 2024
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.2 years ago

Interventions

Eversense® CGM Systemdevice

Continuous Glucose monitoring device